Aims: Oxidative stress plays a pivotal role in the impaired endothelial function occurring in vascular diseases. Antioxidant strategies induce a clinical advantage in patients with endothelial dysfunction and atherosclerosis and protect from oxidative damage, but the underlying molecular mechanisms have been poorly evaluated. The aim of this study was to analyze the effects and mechanisms of action of antioxidant regimens on endothelial function. Methods and Results: Antioxidant efficacy of N-acetylcysteine, ascorbic acid and propionyl-L-carnitine was evaluated in serum-deprived and TNF-α-stimulated human umbilical vein endothelial cells in vitro. Cell adhesion molecule (CAM) expression was evaluated by blot and real-time PCR, and inflammatory cytokine secretion was evaluated by ELISA; leukocyte adhesion and reactive oxygen species assays and NADPH oxidase 4 isoform (Nox4) expression analyses by blots were also performed. Antioxidant pretreatment restored serum-deprived and TNF-α-induced impaired mitochondrial β-oxidation by reducing flavin adenine dinucleotide level and counteracting increased CAM and Nox4 expression, leukocyte adhesion and inflammatory cytokine secretion. Specific inhibition by plumbagin and siNox4 prevented TNF-α- and serum deprivation-induced detrimental effects, confirming that endothelial oxidative stress and inflammation were Nox4 dependent. Conclusions: Our findings documented Nox4 as a main actor in oxidative stress-induced endothelial dysfunction and further clarify the molecular basis of antioxidant treatment efficacy. © 2014 S. Karger AG, Basel

1.
Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 2005;111:3481-3488.
2.
Chen C, Ochoa LN, Kagan A, Chai H, Liang Z, Lin PH, Yao Q: Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Atherosclerosis 2012;222:74-83.
3.
Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
4.
Kawashima S: Malfunction of vascular control in lifestyle-related diseases: endothelial nitric oxide (NO) synthase/NO system in atherosclerosis. J Pharmacol Sci 2004;96:411-419.
5.
Orlandi A, Marcellini M, Spagnoli LG: Aging influences development and progression of early aortic atherosclerotic lesions in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 2000;20:1123-1136.
6.
Addabbo F, Ratliff B, Park HC, Kuo MC, Ungvari Z, Csiszar A, Krasnikov B, Sodhi K, Zhang F, Nasjletti A, et al: The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. Am J Pathol 2009;174:34-43.
7.
Dikalov S: Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med 2011;51:1289-1301.
8.
Santos CX, Tanaka LY, Wosniak J, Laurindo FR: Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009;11:2409-2427.
9.
Madamanchi NR, Runge MS: Mitochondrial dysfunction in atherosclerosis. Circ Res 2007;100:460-473.
10.
Kim JA, Wei Y, Sowers JR: Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008;102:401-414.
11.
Doughan AK, Harrison DG, Dikalov SI: Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008;102:488-496.
12.
Kvietys PR, Granger DN: Role of reactive oxygen and nitrogen species in the vascular responses to inflammation. Free Radic Biol Med 2012;52:556-592.
13.
Bourcier T, Sukhova G, Libby P: The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997;272:15817-15824.
14.
Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ: NADPH oxidases in vascular pathology. Antioxid Redox Signal 2014;20:2794-2814.
15.
Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M: Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004;109:227-233.
16.
Stasi MA, Scioli MG, Arcuri G, Mattera GG, Lombardo K, Marcellini M, Riccioni T, De Falco S, Pisano C, Spagnoli LG, et al: Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production. Arterioscler Thromb Vasc Biol 2010;30:426-435.
17.
Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Zuodar G, Ceriello A: Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis 2005;183:259-267.
18.
Zakynthinos E, Pappa N: Inflammatory biomarkers in coronary artery disease. J Cardiol 2009;53:317-333.
19.
Harrington JR: The role of MCP-1 in atherosclerosis. Stem Cells 2000;18:65-66.
20.
Radomska-Lesniewska DM, Sadowska AM, Van Overveld FJ, Demkow U, Zielinski J, De Backer WA: Influence of N-acetylcysteine on ICAM-1 expression and IL-8 release from endothelial and epithelial cells. J Physiol Pharmacol 2006;57(suppl 4):325-334.
21.
Ozkanlar S, Akcay F: Antioxidant vitamins in atherosclerosis - animal experiments and clinical studies. Adv Clin Exp Med 2012;21:115-123.
22.
May JM, Harrison FE: Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal 2013;19:2068-2083.
23.
Delaney CL, Spark JI, Thomas J, Wong YT, Chan LT, Miller MD: A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication. Atherosclerosis 2013;229:1-9.
24.
Brass EP, Koster D, Hiatt WR, Amato A: A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Vasc Med 2013;18:3-12.
25.
Bremer J: Carnitine - metabolism and functions. Physiol Rev 1983;63:1420-1480.
26.
Ribas GS, Vargas CR, Wajner M: L-Carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene 2014;533:469-476.
27.
Li P, Park C, Micheletti R, Li B, Cheng W, Sonnenblick EH, Anversa P, Bianchi G: Myocyte performance during evolution of myocardial infarction in rats: effects of propionyl-L-carnitine. Am J Physiol 1995;268:H1702-H1713.
28.
Scioli MG, Stasi MA, Passeri D, Doldo E, Costanza G, Camerini R, Fociani P, Arcuri G, Lombardo K, Pace S, et al: Propionyl-L-carnitine is efficacious in ulcerative colitis through its action on the immune function and microvasculature. Clin Transl Gastroenterol 2014;5:e55.
29.
Harfouche R, Hasséssian HM, Guo Y, Faivre V, Srikant CB, Yancopoulos GD, Hussain SN: Mechanisms which mediate the antiapoptotic effects of angiopoietin-1 on endothelial cells. Microvasc Res 2002;64:135-147.
30.
Stangl V, Gunther C, Jarrin A, Bramlage P, Moobed M, Staudt A, Baumann G, Stangl K, Felix SB: Homocysteine inhibits TNF-alpha-induced endothelial adhesion molecule expression and monocyte adhesion via nuclear factor-kappaB dependent pathway. Biochem Biophys Res Commun 2001;280:1093-1100.
31.
Campagnolo L, Costanza G, Francesconi A, Arcuri G, Moscatelli I, Orlandi A: Sortilin expression is essential for pro-nerve growth factor-induced apoptosis of rat vascular smooth muscle cells. PloS One 2014;9:e84969.
32.
Matera MG, Calzetta L, Passeri D, Facciolo F, Rendina EA, Page C, Cazzola M, Orlandi A: Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol 2011;163:1740-1754.
33.
Tarallo V, Vesci L, Capasso O, Esposito MT, Riccioni T, Pastore L, Orlandi A, Pisano C, De Falco S: A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 2010;70:1804-1813.
34.
Drummond GR, Selemidis S, Griendling KK, Sobey CG: Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-471.
35.
Hirase T, Node K: Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol 2012;302:H499-H505.
36.
Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
37.
Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, Shah AM: Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res 2002;90:143-150.
38.
Deng B, Xie S, Wang J, Xia Z, Nie R: Inhibition of protein kinase C beta(2) prevents tumor necrosis factor-alpha-induced apoptosis and oxidative stress in endothelial cells: the role of NADPH oxidase subunits. J Vasc Res 2012;49:144-159.
39.
Takemura Y, Goodson P, Bao HF, Jain L, Helms MN: Rac1-mediated NADPH oxidase release of O2- regulates epithelial sodium channel activity in the alveolar epithelium. Am J Physiol Lung Cell Mol Physiol 2010;298:L509-L520.
40.
Basuroy S, Bhattacharya S, Leffler CW, Parfenova H: Nox4 NADPH oxidase mediates oxidative stress and apoptosis caused by TNF-alpha in cerebral vascular endothelial cells. Am J Physiol Cell Physiol 2009;296:C422-C432.
41.
Tong X, Hou X, Jourd'heuil D, Weisbrod RM, Cohen RA: Upregulation of Nox4 by TGF{beta}1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. Circ Res 2010;107:975-983.
42.
Hordijk PL: Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 2006;98:453-462.
43.
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB: Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 2014;20:1126-1167.
44.
Orlandi A, Bennett M: Progenitor cell-derived smooth muscle cells in vascular disease. Biochem Pharmacol 2010;79:1706-1713.
45.
Ferlosio A, Arcuri G, Doldo E, Scioli MG, De Falco S, Spagnoli LG, Orlandi A: Age-related increase of stem marker expression influences vascular smooth muscle cell properties. Atherosclerosis 2012;224:51-57.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.